CIT expands US presence

Appoints vice-president of business development North America

CIT, a French non-clinical CRO, has opened a US subsidiary, CITox, in Boston, Massachusetts, to spearhead the planned expansion of its US activities.

The company has appointed Bernard Galat as vice-president, business development, North America, who will be based in the Boston office.

The US represents 15% of CIT’s current sales; the aim is to increase this to 30% in three to five years.

Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron, Parexel and Carestat.

‘This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models,’ he said.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Finance

Lonza to expand bioscience testing offering with the acquisition of Redberry

Acquisition to include Red One solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for pharmaceutical quality control (QC)
Research & Development

Piramal Pharma Solutions formalises partnership with IntoCell

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
Subscribe now